Skip to content

Tarsus Pharmaceuticals, Inc. TARS Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant

Common Stock, Capital Shares Reserved for Future Issuance, Effect Of Stock Awards Available For Future Grant at other companies

U.S. Bancorp logo
U.S. BancorpUSB
52M-11.9%
Mondelez International logo
Mondelez InternationalMDLZ
68.1M-5.3%
PepsiCo logo
PepsiCoPEP
89M-6.3%
PNC Financial Services logo
PNC Financial ServicesPNC
77M-1.3%
Bank of America logo
Bank of AmericaBAC
498M+5.5%
Rockwell Automation logo
Rockwell AutomationROK
10.6M-13.1%

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfStockAwardsAvailableForFutureGrant.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance, effect of stock awards available for future grant.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance, effect of stock awards available for future grant?
Tarsus Pharmaceuticals, Inc. (TARS) reported common stock, capital shares reserved for future issuance, effect of stock awards available for future grant of 7.9M in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance, effect of stock awards available for future grant changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance, effect of stock awards available for future grant increased by 9.3% year-over-year, from 7.3M to 7.9M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance, effect of stock awards available for future grant?
Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s common stock, capital shares reserved for future issuance, effect of stock awards available for future grant has grown at a -5.6% compound annual growth rate (CAGR), from 9.4M to 7M.
What does common stock, capital shares reserved for future issuance, effect of stock awards available for future grant mean?
This reflects the volume of common shares set aside for future issuance, specifically related to potential stock awards not yet granted. It serves as a measure of the company's 'overhang' or potential dilution from future equity-based compensation programs. Investors monitor this to gauge the company's long-term incentive strategy and its impact on share count.